Pamorelin LA

Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) that functions as a potent agonist, initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) before causing receptor downregulation and subsequent suppression of gonadotropin secretion, thereby reducing testosterone levels in men and estrogen levels in women.[1][2] Primarily indicated for the palliative treatment of advanced prostate cancer through androgen deprivation therapy, it achieves castrate levels of testosterone, slowing cancer progression and alleviating symptoms such as bone pain.[3][4] Triptorelin is also approved for treating central precocious puberty in children by delaying puberty onset and reducing associated growth accelerations.[5] Administered via intramuscular depot injections (e.g., as Trelstar or Decapeptyl) at intervals of 1, 3, or 6 months, it demonstrates sustained efficacy in maintaining hormone suppression, though initial flare-ups may require anti-androgen co-therapy to mitigate transient tumor stimulation.[6][7] Common adverse effects include hot flashes, fatigue, and injection-site reactions, reflecting its impact on sex hormone pathways.[1]